Published: Jan. 1, 2024
Language: Английский
Current Oncology, Journal Year: 2023, Volume and Issue: 30(6), P. 5704 - 5718
Published: June 11, 2023
Immunotherapy is a promising therapeutic domain for the treatment of gliomas. However, clinical trials various immunotherapeutic modalities have not yielded significant improvements in patient survival. Preclinical models glioma research should faithfully represent clinically observed features regarding behavior, mutational load, tumor interactions with stromal cells, and immunosuppressive mechanisms. In this review, we dive into common preclinical used immunology, discuss their advantages disadvantages, highlight examples utilization translational research.
Language: Английский
Citations
7
Journal of Cancer Research and Clinical Oncology, Journal Year: 2024, Volume and Issue: 150(4)
Published: April 22, 2024
Abstract Purpose To investigate and compare the dynamic positron emission tomography (PET) imaging with [ 18 F]Alfatide II Imaging 11 C]Methionine ([ C]MET) in orthotopic rat models of glioblastoma multiforme (GBM), to assess utility detecting evaluating neoangiogenesis GBM. Methods C]MET were injected into GBM ( n = 20, C6 glioma cells), followed by PET/MR scans 21 days after surgery tumor implantation. On PET image both radiotracers, MRI-based volume-of-interest (VOI) was manually delineated encompassing glioblastoma. Time-activity curves expressed as tumor-to-normal brain ratio (TNR) parameters pharmacokinetic modeling (PKM) performed using 2-tissue-compartment (2TCM). Immunofluorescent staining (IFS), western blotting blocking experiment tissue for validation. Results Compared C-MET, presented a persistent accumulation tumor, albeit slightly lower SUVmean 0.79 ± 0.25, reduced uptake contralateral normal tissue, respectively. This resulted markedly higher 18.22 1.91. The time–activity curve (TACs) showed significant increase radioactive plateau phase up 60 min (time peak:255 s) 40 peak:135 post injection. PKM confirmed significantly K 1 (0.23/0.07) 3 (0.26/0.09) region compared II. imaging, /K 2 (1.24 0.79/1.05 0.39) 4 (11.93 4.28/3.89 1.29) IFS expression integrin vascularization region. Conclusion demonstrates potential tumor-associated neovascularization context suggesting its tool further exploration neovascular characterization.
Language: Английский
Citations
1
Journal of Translational Medicine, Journal Year: 2024, Volume and Issue: 22(1)
Published: Oct. 21, 2024
Interleukin-18, a member of the interleukin − 1 family cytokines, is upregulated in glioma. However, its effects on glioma remain unclear. This study aimed to explore role and underlying mechanisms interleukin-18 expression Here, we demonstrated that enhanced resistance temozolomide by increasing proliferation inhibiting apoptosis cultured cells. Further vivo studies revealed promoted BALB/c nude mice bearing tumor. Mechanical exploration indicated stimulation could activate PI3K/AKT signaling pathway cells, PI3K inhibition reduce interleukin-18. We found CD274 glioma, revealing potential microenvironment. Furthermore, established tumor xenograft model explored therapeutic efficacy anti-interleukin-18 monoclonal antibody. Targeting prolonged survival attenuated Combined treatment with anti-PD-1 antibody showed better suppressing growth than either alone Collectively, these data present promotes chemoresistance cells via PI3K/Akt activation establishes an immunosuppressive milieu modulating CD274. highlights value
Language: Английский
Citations
1
Drug Discovery Today, Journal Year: 2024, Volume and Issue: unknown, P. 104219 - 104219
Published: Oct. 1, 2024
Language: Английский
Citations
1
Biomedicines, Journal Year: 2024, Volume and Issue: 12(11), P. 2631 - 2631
Published: Nov. 17, 2024
Despite the great advances in basic research results, glioblastoma multiforme (GBM) still remains an incurable tumour. To date, a GBM diagnosis is death sentence within 15-18 months, due to high recurrence rate and resistance conventional radio- chemotherapy approaches. The effort scientific community lavishing on never-ending battle against reflected by huge number of clinical trials launched, about 2003 10 September 2024. However, we are far from both in-depth comprehension biological molecular processes leading onset progression and, importantly, cure. provided with intratumoral heterogeneity, immunosuppressive capacity, infiltrative ability neoangiogenesis. These features impact tumour aggressiveness therapeutic vulnerability, which further limited presence core niches stem cells (GSCs) that responsible for relapse this brain neoplasm. Epigenetic alterations may drive develop along also rely changes expression genes encoding histone-modifying enzymes, including histone deacetylases (HDACs). Among them, HDAC6-a cytoplasmic HDAC-has recently gained attention because its role modulating several aspects GBM, DNA repair ability, massive growth, chemoresistance, de-differentiation through primary cilia disruption. In review article, available information related HDAC6 function will be presented, aim proposing inhibition as valuable route deadly
Language: Английский
Citations
1
Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown
Published: April 17, 2024
Language: Английский
Citations
0
Published: Jan. 1, 2024
Language: Английский
Citations
0